Tarlatamab trials for Small Cell Lung Cancer

All Tarlatamab trials · All Small Cell Lung Cancer trials

Phase breakdown

Recruiting trials studying Tarlatamab for Small Cell Lung Cancer

• A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
  NCT07005128 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 164 locations
• Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)
  NCT07778316 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 2 locations
• Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
  NCT07531095 · Phase: Phase 1 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 27 locations
• Study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor Performance Status
  NCT07803848 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• Tarlatamab for SCLC Brain Metastases
  NCT07402343 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations

Common questions

How many trials study Tarlatamab for Small Cell Lung Cancer?

5 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.